Dr. Daniel F. Sousa, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Vermont College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 689
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Vermont College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
MA license 217398 -
Pulmonary Disease Physician
MA license 217398 · RI license MD10789
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Southcoast Hospitals Group Fall River, MA
- Newport Hospital Newport, RI
Medical groups
- Southcoast Physicians Group Inc (881 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 689
- Services billed
- 1,791
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 741 | 471 |
| Critical care, first 30-74 minutes | 214 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 163 | 81 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 145 | 145 |
| Test to examine how well the lungs exchange gases | 97 | 97 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 83 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 77 | 76 |
| Test to determine lung volumes using sensors | 68 | 68 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Fall River, MA | 508 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Fall River, MA | 494 |
| Montelukast Sodium Other prescribers in Fall River, MA | 318 |
| Prednisone Other prescribers in Fall River, MA | 237 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Fall River, MA | 182 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Fall River, MA | 161 |
| Azithromycin Other prescribers in Fall River, MA | 130 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Fall River, MA | 123 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Fall River, MA | 118 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Fall River, MA | 102 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $199 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $140 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $59.30 |
| Food and Beverage | $199 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $249,049 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, parallel group, multi-center study to eval
GlaxoSmithKline, LLC. - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - Ph IIb of Astegolimab in COPD
Genentech, Inc. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A randomized, double-blind, placebo-controlled, parallel-group, multic
GlaxoSmithKline, LLC. - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
AstraZeneca Pharmaceuticals LP - Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Sanofi US Services Inc. · Completed · NCT04456673
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.